Abstract: The present disclosure provides a risk assessment method of water inrush in tunnels constructed in water-rich grounds. The method includes the following steps: simulating a tunnel excavation process by finite element software MIDAS GTS NX and fluid-structure interaction; according to a research method of control variables, analyzing effects of a groundwater level, an elastic modulus and advanced pipe shed grouting on the stability of surrounding rock, and improving an algorithm of a radial basis function (RBF) neural network using a Grey Relation Analysis (GRA)-based Partitioning Around Medoid (PAM) clustering algorithm to assess risks of water inrush occurring in Qingdao area.

Abstract: A data transmission method includes: determining, by a regional access device, a message that needs to be transmitted includes M pieces of QoS information; and after the regional access device determines that a device identifier in a first piece of QoS information is consistent with a device identifier of the regional access device, updating a QoS value of the message that needs to be transmitted with a first QoS value in the first piece of QoS information, and forwarding the updated message that needs to be transmitted. The first piece of QoS information is any one of the M pieces of QoS information.

Abstract: The present invention relates to a molecular marker, a specific primer pair, and an identification method of the high-quality Ganoderma lucidum strain HMGIM-M624. The high-quality Ganoderma lucidum strain HMGIM-M624 was preserved in Guangdong Microbial Culture Collection Center (address: 5th Floor, No. 59 Building of No. 100 Yard, Mid. Xianlie Road, Guangzhou City) with the preservation number of GDMCC No: 60889 on Nov. 7, 2019. The molecular marker is an InDel molecular marker. The high-quality Ganoderma lucidum strain HMGIM-M624 has a base deletion of CATGCTGTA at the 246451th-246460th site of the chromosome sca34. The present invention provides reagents for detecting the molecular marker of the high-quality Ganoderma lucidum strain HMGIM-M624. The reagents can distinguish the high-quality Ganoderma lucidum strain HMGIM-M624 from the other 11 G. lucidum strains for commercial cultivation, thus specifically identifying the high-quality Ganoderma lucidum strain HMGIM-M624.

Abstract: The present disclosure provides an arctigenin liquid nano-preparation and a preparation method thereof, and relates to the technical field of pharmaceutical preparation. In the present disclosure, arctigenin is prepared into a liquid nano-preparation, having advantages of distribution of a droplet diameter on nanoscale, significantly increased specific surface area, rapid absorption, and high bioavailability. Meanwhile, nano-preparation entered the body can be captured by wandering leucocytes, and a medicament is delivered to inflammatory lesions through chemiotaxis, thereby conferring a targeted drug delivery feature on the arctigenin and making a therapy more targeted. Moreover, in the present disclosure, the arctigenin is dissolved in an oil phase, and the oil phase is dissolved in water by emulsification to further make the arctigenin dissolve in the water and increase water solubility of the arctigenin.

Abstract: The present disclosure provides compounds that are cGAS antagonists, methods of preparation of the compounds, pharmaceutical compositions comprising the compounds, and their use in medical therapy.

Abstract: An electronic device may have a phased antenna array. An antenna in the array may include a rectangular patch element with diagonal axes. The antenna may have first and second antenna feeds coupled to the patch element along the diagonal axes. The antenna may be rotated at a forty-five degree angle relative to other antennas in the array. The antenna may have one or two layers of parasitic elements overlapping the patch element. For example, the antenna may have a layer of coplanar parasitic patches separated by a gap. The antenna may also have an additional parasitic patch that is located farther from the patch element than the layer of coplanar parasitic patches. The additional parasitic patch may overlap the patch element and the gap in the coplanar parasitic patches. The antenna may exhibit a relatively small footprint and minimal mutual coupling with other antennas in the array.

Abstract: The present invention is directed to a monoclonal mouse or humanized ROR1 antibody, or a single-chain variable fragment (scFv). The present invention is also directed to a mouse or humanized ROR1 chimeric antigen receptor (CAR) comprising from N-terminus to C-terminus: (i) a single-chain variable fragment (scFv) of the present invention, (ii) a transmembrane domain, (iii) at least one co-stimulatory domains, and (iv) an activating domain.

Abstract: An electronic device may be provided with a phased antenna array on an antenna module. The array may include low band antennas and high band antennas that radiate at frequencies greater than 10 GHz. The module may include antenna layers, transmission line layers, and ground traces that separate the antenna layers from the transmission line layers. The low band antennas and the high band antennas may have radiators patterned onto the antenna layers. The radiators may be fed by transmission lines on the transmission line layers. The antenna layers may have a dielectric permittivity that is greater than the dielectric permittivity of the transmission line layers. This may serve to reduce the lateral footprint of the low band and high band antennas, which allows the antennas to be interleaved along a common linear axis in the phased antenna array, thereby minimizing the lateral footprint of the antenna module.

Abstract: The present invention is directed to a humanized BCMA antibody or an antigen-binding fragment thereof, comprising VH having the amino acid sequence of SEQ ID NO: 3 and VL having the amino acid sequence of SEQ ID NO: 5. The present invention is also directed to a BCMA chimeric antigen receptor fusion protein comprising from N-terminus to C-terminus: (i) a single-chain variable fragment (scFv) of the present invention, (ii) a transmembrane domain, (iii) at least one co-stimulatory domains, and (iv) an activating domain. This humanized BCMA-CAR-T cells have specific killing activity against BCMA-positive tumor cells.

Abstract: The present invention is directed to a monoclonal mouse or humanized ROR1 antibody, or a single-chain variable fragment (scFv). The present invention is also directed to a mouse or humanized ROR1 chimeric antigen receptor (CAR) comprising from N-terminus to C-terminus: (i) a single-chain variable fragment (scFv) of the present invention, (ii) a transmembrane domain, (iii) at least one co-stimulatory domains, and (iv) an activating domain.

Abstract: The present invention is directed to a humanized BCMA single-chain variable fragment (scFv), comprising VH having the amino acid sequence of SEQ ID NO: 4 and VL having the amino acid sequence of SEQ ID NO: 5. The present invention is also directed to a BCMA chimeric antigen receptor fusion protein comprising from N-terminus to C-terminus: (i) a single-chain variable fragment (scFv) of the present invention, (ii) a transmembrane domain, (iii) at least one co-stimulatory domains, and (iv) an activating domain. A preferred co-stimulatory domain is CD28 or 41-BB. The humanized BCMA-CAR-T cells have specific killing activity with secretion of cytokine IFN-gamma in CAR-T cells in vitro and in vivo.

Abstract: The present invention is directed to a monoclonal anti-human CS1 clone 7A8D5 antibody or a single-chain variable fragment (scFv), comprising VH having the amino acid of SEQ ID NO: 4 and VL having the amino acid of SEQ ID NO: 5. The present invention is also directed to a chimeric antigen receptor fusion protein comprising from N-terminus to C-terminus: (i) CS1 scFv of the present invention, (ii) a transmembrane domain, (iii) at least one co-stimulatory domains, and (iv) an activating domain.

Abstract: The present invention is directed to humanized CD37-CAR comprising humanized CD37 scFv of the present invention. The present invention is also directed to a bispecific CD19-humanized CD37 CAR, comprising: (i) CD19 VL, (ii) Humanized CD37 ScFv, (iii) CD19 VH, (iv) a transmembrane domain, (v) at least one co-stimulatory domains, and (vi) an activating domain. The CARs of the present invention are useful in the field of adoptive immunity gene therapy for hematological cancers.

Abstract: The present invention is directed to a chimeric antigen receptor fusion protein comprising: (i) a single-chain variable fragment (scFv) comprising VH and VL, wherein scFv has an activity against a tumor antigen, (ii) a transmembrane domain, (iii) at least one co-stimulatory domains, and (iv) an activating domain; wherein the CAR further comprises a human transferrin fragment, which is an epitope for an antibody against human transferrin, at N-terminus or C-terminus to scFv, or between VH and VL. Preferred tumor antigens are CD19, CD22 and BCMA. The CD19-TF-CAR-T cells, CD22-TF-CAR-T cells, and BAMA-TF CAR-T cells secrete less cytokines, but they have the same efficacy against cancer target cells when comparing with same CAR without TF.

Abstract: The present invention is directed to a monoclonal anti-human PD-L1 antibody, or a single-chain variable fragment (scFv), comprising VH having the amino acid of SEQ ID NO: 3 and VL having the amino acid of SEQ ID NO: 5. The present invention is also directed to a chimeric antigen receptor fusion protein comprising from N-terminus to C-terminus: (i) a single-chain variable fragment (scFv) of the present invention, (ii) a transmembrane domain, (iii) at least one co-stimulatory domains, and (iv) an activating domain. The inventors have shown that the PD-L1 CAR-T cells of the present invention are more effective than Avelumab PD-L1 CAR-T cells in killing several cancer cell lines. PD-L1 CAR-T can be used alone or in combination with other agent in an immunotherapy.

Abstract: The present invention provides a chimeric antigen receptor (CAR) fusion protein comprising from N-terminus to C-terminus: (i) a single-chain variable fragment (scFv) comprising VH and VL, wherein scFv has an activity against CD47, (ii) a transmembrane domain, (iii) at least one co-stimulatory domains, and (iv) an activating domain. In one embodiment, the scFv is derived from a humanized anti-CD47 antibody. The present invention also provides T cells modified to express the CAR of the present invention.

Abstract: The present invention discloses systems and methods for supplying hot water for primary extraction in the oil sands bitumen extraction process. Direct contact process and method for producing hot water using mature fine tailings are provided by employing a double staged submerge arrangement with a thickener vessel containing a submerged fuel burner and a hot water vessel containing a submerged fuel burner, a flash submerged arrangement with a flash concentrator vessel containing or adjacent to a fuel burner and a hot water vessel containing a submerged fuel burner or a triple cascade arrangement with a flash concentrator vessel, a thickener vessel containing a submerged fuel burner and a hot water vessel containing a submerged fuel burner.

Abstract: The present invention is directed to a humanized BCMA single-chain variable fragment (scFv), comprising VH having the amino acid sequence of SEQ ID NO: 4 and VL having the amino acid sequence of SEQ ID NO: 5. The present invention is also directed to a BCMA chimeric antigen receptor fusion protein comprising from N-terminus to C-terminus: (i) a single-chain variable fragment (scFv) of the present invention, (ii) a transmembrane domain, (iii) at least one co-stimulatory domains, and (iv) an activating domain. This humanized BCMA-CAR-T cells have specific killing activity with secretion of cytokine IFN-gamma in CAR-T cells in vitro and in vivo.

Abstract: The present invention is directed to bispecific humanized PLAP (placental alkaline phosphatase)-CD3 epsilon chain (CD3e) antibodies. The present invention is further directed to a method for treating PLAP-positive cancer cells by administering the bispecific PLAP-CD3e antibody to the patients.

Abstract: The present invention is directed to a humanized BCMA single-chain variable fragment (scFv), comprising VH having the amino acid sequence of SEQ ID NO: 3 and VL having the amino acid sequence of SEQ ID NO: 5. The present invention is also directed to a BCMA chimeric antigen receptor fusion protein comprising from N-terminus to C-terminus: (i) a single-chain variable fragment (scFv) of the present invention, (ii) a transmembrane domain, (iii) at least one co-stimulatory domains, and (iv) an activating domain. This humanized BCMA-CAR-T cells have specific killing activity against BCMA-positive tumor cells.